Previous studies validated that CCL2 [38], IL10 [39], CD163 [40], and NRP1 [41] had adverse influence on progression and prognosis of BLCA, while CSF1R antagonist had been used in treatment of urothelial bladder cancers [42]. The gene discussed is NRP1; the disease is bladder transitional cell carcinoma.